Abstract

Continuous glucose monitoring (CGM) technology provides real-time glucose concentration data to people with diabetes. The data enable timely treatment decisions that can lead to avoidance or mitigation of hypoglycaemia, with potential cost savings. This commentary discusses CGM implementation and funding policies in the UK, and regional disparities that confront many people with diabetes who could benefit from the technology.

Keywords

Continuous glucose monitoring, commissioning, hypoglycaemia

Disclosure

Nick Oliver has received research support from Dexcom, Inc. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the editorial board for accuracy before publication.

Open Access

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original.

Received

July 03, 2017

Published Online

August 22, 2017

Correspondence

Nick Oliver, Section of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, Du Cane Road, London, W12 0HS, UK. E: Nick.oliver@imperial.ac.uk

Support

The publication of this article was supported by Dexcom, Inc. The views and opinions expressed are those of the author and do not necessarily reflect those of Dexcom, Inc.